Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PARETEUM CorpTEUM · Entity 144276 | Director | February 19, 2017 | February 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PARETEUM Corp
Report date February 19, 2017 · Filed February 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 451,949 |
Reported balance
After 2017-02-19 transaction · row 1
1 source rowRow 1 · 2017-02-19 · Purchase · Acquired 275,911 · Balance 451,949 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 567,186 |
Reported balance
After 2026-10-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 225,670 · Balance 567,186 F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 804,646 |
Reported balance
After 2026-10-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 237,460 · Balance 804,646 F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 439,774 |
Reported balance
After 2026-10-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-10-06 · Tax withholding · Disposed 364,872 · Balance 439,774 F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-10-06 · Disposition to issuer · Disposed 826,454 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2020 Filed Nov 17, 2020 02:21 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001437749-20-024044 · rdgdoc.xml · derivative · entry 9 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vested 25% on March 4, 2017 and thereafter, in 36 equal monthly installments. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 02:21 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $31.33 | $313,300.00 |
DisclosureSEC source: 0001437749-20-024044 · rdgdoc.xml · nonDerivative · entry 6 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,293 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.75 to $31.90, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 02:21 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.76 | $17,600.00 |
DisclosureSEC source: 0001437749-20-024044 · rdgdoc.xml · nonDerivative · entry 5 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 02:21 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001437749-20-024044 · rdgdoc.xml · derivative · entry 8 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vested 25% on March 4, 2017 and thereafter, in 36 equal monthly installments. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 02:21 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $31.87 | $318,700.00 |
DisclosureSEC source: 0001437749-20-024044 · rdgdoc.xml · nonDerivative · entry 4 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,293 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.65 to $32.28, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 02:21 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.76 | $17,600.00 |
DisclosureSEC source: 0001437749-20-024044 · rdgdoc.xml · nonDerivative · entry 3 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2020 Filed Nov 17, 2020 02:21 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001437749-20-024044 · rdgdoc.xml · derivative · entry 7 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vested 25% on March 4, 2017 and thereafter, in 36 equal monthly installments. Read SEC document |
| November 12, 2020 Filed Nov 17, 2020 02:21 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $32.10 | $321,000.00 |
DisclosureSEC source: 0001437749-20-024044 · rdgdoc.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,293 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.76 to $32.45, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 12, 2020 Filed Nov 17, 2020 02:21 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.76 | $17,600.00 |
DisclosureSEC source: 0001437749-20-024044 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 01:41 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,781 | $28.63 | $50,990.03 |
DisclosureSEC source: 0001437749-20-020643 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,293 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 22, 2020 Filed Jul 25, 2020 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-015717 · rdgdoc.xml · derivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock was granted pursuant to the BioLife Solutions Inc. Second Amended and Restated 2013 Performance Incentive Plan, as amended, and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. F1 · derivative.expiration_date: The restricted stock was granted pursuant to the BioLife Solutions Inc. Second Amended and Restated 2013 Performance Incentive Plan, as amended, and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. Read SEC document |
| July 22, 2020 Filed Nov 17, 2020 02:13 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-024043 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,074 F1 · security: This Form 4/A is being filed to amend the Form 4 (the "Original Form 4") filed by the reporting person on July 24, 2020 to include the restricted stock grant that was granted on July 22, 2020 pursuant to the BioLife Solutions Inc. Second Amended and Restated 2013 Performance Incentive Plan, on Table I rather than Table II. As described in the Original Form 4, the restricted stock vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The information included in column 5 of this Form 4/A reflects the number of securities beneficially owned following the reported transaction on July 22, 2020 assuming all of the restricted shares vested. F1 · price: This Form 4/A is being filed to amend the Form 4 (the "Original Form 4") filed by the reporting person on July 24, 2020 to include the restricted stock grant that was granted on July 22, 2020 pursuant to the BioLife Solutions Inc. Second Amended and Restated 2013 Performance Incentive Plan, on Table I rather than Table II. As described in the Original Form 4, the restricted stock vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The information included in column 5 of this Form 4/A reflects the number of securities beneficially owned following the reported transaction on July 22, 2020 assuming all of the restricted shares vested. Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 13,154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-006397 · rdgdoc.xml · derivative · entry 5 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,154 Underlying: Common Stock · 13,154 shares Expires not disclosed F5 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 125% of the reported number of shares in column 5 based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. This restricted stock was granted in lieu of such reporting person receiving a 2020 cash performance bonus. F5 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 125% of the reported number of shares in column 5 based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. This restricted stock was granted in lieu of such reporting person receiving a 2020 cash performance bonus. Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 21,923 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-006397 · rdgdoc.xml · derivative · entry 4 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,923 Underlying: Common Stock · 21,923 shares Expires not disclosed F4 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2021 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F4 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2021 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 21,923 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-006397 · rdgdoc.xml · nonDerivative · entry 3 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,074 F3 · security: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. F3 · price: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 5,359 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-006397 · rdgdoc.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,151 F2 · security: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. F2 · price: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 4,933 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-006397 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,792 F1 · security: The restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") and vests in full on September 25, 2020. This restricted stock was granted to the reporting person in lieu of such reporting person's 2019 cash performance bonus. F1 · price: The restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") and vests in full on September 25, 2020. This restricted stock was granted to the reporting person in lieu of such reporting person's 2019 cash performance bonus. Read SEC document |
| March 06, 2020 Filed Mar 7, 2020 01:24 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001437749-20-004539 · rdgdoc.xml · derivative · entry 9 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 10,000 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| March 06, 2020 Filed Mar 7, 2020 01:24 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $13.77 | $137,700.00 |
DisclosureSEC source: 0001437749-20-004539 · rdgdoc.xml · nonDerivative · entry 6 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,859 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2018. Read SEC document |
| March 06, 2020 Filed Mar 7, 2020 01:24 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.81 | $18,100.00 |
DisclosureSEC source: 0001437749-20-004539 · rdgdoc.xml · nonDerivative · entry 5 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2020 Filed Mar 7, 2020 01:24 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001437749-20-004539 · rdgdoc.xml · derivative · entry 8 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 10,000 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| March 05, 2020 Filed Mar 7, 2020 01:24 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $13.72 | $137,200.00 |
DisclosureSEC source: 0001437749-20-004539 · rdgdoc.xml · nonDerivative · entry 4 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,859 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.60 to $14.00 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 05, 2020 Filed Mar 7, 2020 01:24 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.81 | $18,100.00 |
DisclosureSEC source: 0001437749-20-004539 · rdgdoc.xml · nonDerivative · entry 3 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 01:24 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001437749-20-004539 · rdgdoc.xml · derivative · entry 7 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 10,000 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 01:24 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $13.95 | $139,500.00 |
DisclosureSEC source: 0001437749-20-004539 · rdgdoc.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,859 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.85 to $14.01 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 01:24 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.81 | $18,100.00 |
DisclosureSEC source: 0001437749-20-004539 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2020 Filed Feb 8, 2020 02:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001437749-20-002103 · rdgdoc.xml · derivative · entry 9 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 10,000 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| February 07, 2020 Filed Feb 8, 2020 02:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $13.32 | $133,200.00 |
DisclosureSEC source: 0001437749-20-002103 · rdgdoc.xml · nonDerivative · entry 6 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,859 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.55 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 07, 2020 Filed Feb 8, 2020 02:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.81 | $18,099.00 |
DisclosureSEC source: 0001437749-20-002103 · rdgdoc.xml · nonDerivative · entry 5 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 02:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001437749-20-002103 · rdgdoc.xml · derivative · entry 8 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,000 Underlying: Common Stock · 10,000 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 02:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $14.43 | $144,300.00 |
DisclosureSEC source: 0001437749-20-002103 · rdgdoc.xml · nonDerivative · entry 4 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,859 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.26 to $14.84 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 02:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.81 | $18,099.00 |
DisclosureSEC source: 0001437749-20-002103 · rdgdoc.xml · nonDerivative · entry 3 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2020 Filed Feb 8, 2020 02:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001437749-20-002103 · rdgdoc.xml · derivative · entry 7 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,000 Underlying: Common Stock · 10,000 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| February 05, 2020 Filed Feb 8, 2020 02:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $14.06 | $140,600.00 |
DisclosureSEC source: 0001437749-20-002103 · rdgdoc.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,859 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.02 to $14.23 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 05, 2020 Filed Feb 8, 2020 02:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.81 | $18,099.00 |
DisclosureSEC source: 0001437749-20-002103 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001437749-20-000364 · rdgdoc.xml · derivative · entry 9 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date and thereafter, in 36 equal monthly installments. Such options shall continue to vest regardless of whether Mr. de Greef's service with the Company continues Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $16.16 | $161,600.00 |
DisclosureSEC source: 0001437749-20-000364 · rdgdoc.xml · nonDerivative · entry 6 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,859 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.29 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.76 | $17,600.00 |
DisclosureSEC source: 0001437749-20-000364 · rdgdoc.xml · nonDerivative · entry 5 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2020 Filed Feb 8, 2020 02:53 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001437749-20-002102 · rdgdoc.xml · derivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,000 Underlying: Common Stock · 10,000 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4/A is being filed to amend the Form 4 filed by the reporting person on January 8, 2020 to (i) attribute the stock option exercise that occurred on January 8, 2020 to the correct Employee Stock Option and (ii) include the appropriate price in column 4 of Table I representing the exercise price of such Employee Stock Option. F2 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| January 08, 2020 Filed Feb 8, 2020 02:53 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.81 | $18,099.00 |
DisclosureSEC source: 0001437749-20-002102 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4/A is being filed to amend the Form 4 filed by the reporting person on January 8, 2020 to (i) attribute the stock option exercise that occurred on January 8, 2020 to the correct Employee Stock Option and (ii) include the appropriate price in column 4 of Table I representing the exercise price of such Employee Stock Option. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001437749-20-000364 · rdgdoc.xml · derivative · entry 8 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date and thereafter, in 36 equal monthly installments. Such options shall continue to vest regardless of whether Mr. de Greef's service with the Company continues Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $15.46 | $154,600.00 |
DisclosureSEC source: 0001437749-20-000364 · rdgdoc.xml · nonDerivative · entry 4 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,859 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.27 to $15.56 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.76 | $17,600.00 |
DisclosureSEC source: 0001437749-20-000364 · rdgdoc.xml · nonDerivative · entry 3 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2020 Filed Jan 9, 2020 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001437749-20-000364 · rdgdoc.xml · derivative · entry 7 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 10,000 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date and thereafter, in 36 equal monthly installments. Such options shall continue to vest regardless of whether Mr. de Greef's service with the Company continues Read SEC document |
| January 06, 2020 Filed Jan 9, 2020 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $15.90 | $159,000.00 |
DisclosureSEC source: 0001437749-20-000364 · rdgdoc.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,859 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.85 to $15.91 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 06, 2020 Filed Jan 9, 2020 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.76 | $17,600.00 |
DisclosureSEC source: 0001437749-20-000364 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2019 Filed Dec 7, 2019 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001437749-19-024017 · rdgdoc.xml · derivative · entry 9 DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 10,000 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date and thereafter, in 36 equal monthly installments. Such options shall continue to vest regardless of whether Mr. de Greef's service with the Company continues. Read SEC document |
| December 06, 2019 Filed Dec 7, 2019 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $16.21 | $162,100.00 |
DisclosureSEC source: 0001437749-19-024017 · rdgdoc.xml · nonDerivative · entry 6 DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,859 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.15 to $16.24 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 06, 2019 Filed Dec 7, 2019 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.76 | $17,600.00 |
DisclosureSEC source: 0001437749-19-024017 · rdgdoc.xml · nonDerivative · entry 5 DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2019 Filed Dec 7, 2019 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001437749-19-024017 · rdgdoc.xml · derivative · entry 8 DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 10,000 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date and thereafter, in 36 equal monthly installments. Such options shall continue to vest regardless of whether Mr. de Greef's service with the Company continues. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.